Loading...
•
Dec 31, 2023
Day One Q4 2023 Earnings Report
Day One reported Q4 2023 financial results and corporate progress.
Key Takeaways
Day One Biopharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting the upcoming PDUFA date for tovorafenib and continued advancement of the Phase 3 front-line trial. The company ended the year with $366.3 million in cash, providing runway into 2026.
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024.
Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine.
Ended 2023 with $366.3 million in cash, cash equivalents and short-term investments providing runway into 2026.
Day One continued its commercial preparedness for the approval and launch of tovorafenib with the hiring of 18 sales representatives in the U.S.
Forward Guidance
Day One anticipates a monumental year ahead with the upcoming PDUFA date for tovorafenib and continues to advance its Phase 3 front-line trial.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...